ATE243753T1 - Mch4 und mch5, apoptotische proteasen, dafür kodierende nukleinsäure und verfahren zur verwendung - Google Patents

Mch4 und mch5, apoptotische proteasen, dafür kodierende nukleinsäure und verfahren zur verwendung

Info

Publication number
ATE243753T1
ATE243753T1 AT97916063T AT97916063T ATE243753T1 AT E243753 T1 ATE243753 T1 AT E243753T1 AT 97916063 T AT97916063 T AT 97916063T AT 97916063 T AT97916063 T AT 97916063T AT E243753 T1 ATE243753 T1 AT E243753T1
Authority
AT
Austria
Prior art keywords
mch4
mch5
nucleic acid
isolated
acid coding
Prior art date
Application number
AT97916063T
Other languages
English (en)
Inventor
Emad S Alnemri
Teresa Fernandes-Alnemri
Gerald Litwack
Robert Armstrong
Kevin Tomaselli
Original Assignee
Idun Pharmaceuticals Inc
Univ Jefferson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/618,408 external-priority patent/US5851815A/en
Application filed by Idun Pharmaceuticals Inc, Univ Jefferson filed Critical Idun Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE243753T1 publication Critical patent/ATE243753T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
AT97916063T 1996-03-19 1997-03-19 Mch4 und mch5, apoptotische proteasen, dafür kodierende nukleinsäure und verfahren zur verwendung ATE243753T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/618,408 US5851815A (en) 1996-03-19 1996-03-19 MCH4 and MCH5, apoptotic proteases
US08/665,220 US5786173A (en) 1996-03-19 1996-06-14 MCH4 and MCH5, apoptotic protease, nucleic acids encoding and methods of use
PCT/US1997/004330 WO1997035020A1 (en) 1996-03-19 1997-03-19 Mch4 AND Mch5, APOPTOTIC PROTEASE, NUCLEIC ACIDS ENCODING AND METHODS OF USE

Publications (1)

Publication Number Publication Date
ATE243753T1 true ATE243753T1 (de) 2003-07-15

Family

ID=27088226

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97916063T ATE243753T1 (de) 1996-03-19 1997-03-19 Mch4 und mch5, apoptotische proteasen, dafür kodierende nukleinsäure und verfahren zur verwendung

Country Status (8)

Country Link
US (4) US5786173A (de)
EP (1) EP0906434B1 (de)
JP (2) JP4350799B2 (de)
AT (1) ATE243753T1 (de)
AU (1) AU730412B2 (de)
CA (1) CA2249233C (de)
DE (1) DE69723074T2 (de)
WO (1) WO1997035020A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8715645B2 (en) * 1994-05-27 2014-05-06 The Regents Of The University Of Colorado Viral vectors encoding apoptosis-inducing proteins and methods for making and using the same
IL114615A0 (en) * 1995-07-16 1995-11-27 Yeda Res & Dev Modulators of the function of fas receptors and other proteins
US6399327B1 (en) 1995-07-16 2002-06-04 Yeda Research And Development Co. Ltd. Modulators of the function of FAS receptors and other proteins
WO1998000554A1 (en) * 1996-07-03 1998-01-08 Genetics Institute, Inc. Protease fmh-1, an ice/ced-like protease
US6512104B1 (en) * 1996-10-01 2003-01-28 Amgen Inc. Interleukin-1β converting enzyme like cysteine protease
US5837837A (en) * 1997-02-27 1998-11-17 Millennium Pharmaceuticals, Inc. Nucleic acids molecules encoding Caspase-8h and Caspase-8i
EP1100932A2 (de) 1998-07-27 2001-05-23 PHARMACIA & UPJOHN COMPANY Verfahren zur autoaktivierung der procaspase
US7052834B1 (en) 1998-12-31 2006-05-30 St. Jude Children's Research Hospital Tumor suppressor protein involved in death signaling, and diagnostics, therapeutics, and screening based on this protein
AU2222000A (en) * 1998-12-31 2000-07-31 St. Jude Children's Research Hospital A tumor suppressor protein involved in death signaling, and diagnostics, therapeutics, and screening based on this protein
AU5477100A (en) * 1999-06-10 2001-01-02 Pharmacia & Upjohn Company Caspase-8 crystals, models and methods
US6277974B1 (en) 1999-12-14 2001-08-21 Cogent Neuroscience, Inc. Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
CN1300828A (zh) * 1999-12-22 2001-06-27 上海博德基因开发有限公司 一种新的多肽－半胱氨酸蛋白酶10和编码这种多肽的多核苷酸
US6258600B1 (en) 2000-01-19 2001-07-10 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 8 expression
JP2004531731A (ja) * 2001-05-31 2004-10-14 ザ トラスティーズ オブ プリンストン ユニバーシテイ Ｉａｐ結合ペプチドおよびｉａｐに結合する化合物を同定するアッセイ
EP1283052A1 (de) * 2001-08-10 2003-02-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Caspase-8 und/ oder Caspase-9 enthaltende pharmazeutische Zusammenstellung zur Überwindung der glucocorticoid- und krebstherapieinduzierten Tumorresistenz
US20050107451A1 (en) * 2001-12-20 2005-05-19 Portbury Stuart D. Methods for treating conditions, disorders, or diseases involving cell death
EP1391732A1 (de) * 2002-08-23 2004-02-25 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Caspase 10 als Zielstruktur für die Überwachung und Behandlung von Krankheiten
US20040180828A1 (en) * 2003-01-30 2004-09-16 Yigong Shi Caspase-9 : BIR domain of XIAP complexes and methods of use
US20080199439A1 (en) * 2003-02-12 2008-08-21 Mclendon George L IAP-binding cargo molecules and peptidomimetics for use in diagnostic and therapeutic methods
WO2006020060A2 (en) 2004-07-15 2006-02-23 Tetralogic Pharmaceuticals Corporation Iap binding compounds
DK1851200T3 (da) 2005-02-25 2014-04-14 Tetralogic Pharm Corp Dimere iap-inhibitorer
JP2009509128A (ja) * 2005-08-09 2009-03-05 テトラロジック ファーマシューティカルズ コーポレーション 増殖性疾患の治療
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
IL174253A0 (en) * 2006-03-12 2006-08-01 Yeda Res & Dev Use of caspases for the preparation of medicaments
CL2007002167A1 (es) * 2006-07-24 2009-01-23 Tetralogic Pharm Corp Compuestos derivados de indol, antagonistas iap; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de cancer.
US20100056495A1 (en) * 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014240A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
JP5452223B2 (ja) * 2006-07-24 2014-03-26 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ阻害剤
US8283372B2 (en) * 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605826A (en) * 1994-06-10 1997-02-25 Panorama Research, Inc. 24 kilodalton cytoplasmic protease activating DNA fragmentation in apoptosis
IL114615A0 (en) * 1995-07-16 1995-11-27 Yeda Res & Dev Modulators of the function of fas receptors and other proteins

Also Published As

Publication number Publication date
DE69723074T2 (de) 2004-05-13
EP0906434A1 (de) 1999-04-07
EP0906434B1 (de) 2003-06-25
DE69723074D1 (de) 2003-07-31
US6897296B2 (en) 2005-05-24
US6730779B2 (en) 2004-05-04
AU730412B2 (en) 2001-03-08
US5786173A (en) 1998-07-28
US20020035242A1 (en) 2002-03-21
WO1997035020A1 (en) 1997-09-25
CA2249233C (en) 2012-05-22
US20040054148A1 (en) 2004-03-18
US6287795B1 (en) 2001-09-11
JP4350799B2 (ja) 2009-10-21
JP2001508284A (ja) 2001-06-26
JP2008017854A (ja) 2008-01-31
CA2249233A1 (en) 1997-09-25
AU2333197A (en) 1997-10-10

Similar Documents

Publication Publication Date Title
DE69723074D1 (de) Mch4 und mch5, apoptotische proteasen, dafür kodierende nukleinsäure und verfahren zur verwendung
IL131986A0 (en) Shuffling of heterologous dna sequences
DE69731834D1 (de) Agouti verwandtes gen
DE69635444D1 (de) Gereinigte coprinus laccasen und nukleinsäuren welche dafür kodieren
ATE353339T1 (de) Verfahren und zusammensetzung zur hemmung des neoplastischen zellwachstums
DE69930955D1 (de) Polypeptide mit lysophospholipaseaktivität und nukleinesäuren die sie kodieren
DE60033138D1 (de) Polypeptide mit galaktoseoxidaseaktivität und dafür kodierende nukleisäuren
ATE469223T1 (de) Pilz transkriptionsaktivator zur verwendung in verfahren zur herstellung von polypeptiden
DE69833784D1 (de) Polypeptide mit aminopeptidaseaktivität und für diese kodierende nukleinsäuren
DE69840230D1 (de) Polypeptide mit prolyldipeptidylaminopeptidase-aktivität und dafür kodierende nukleinsäuren
ATE335086T1 (de) Künstliche chromosomen, die die genetische information für die bildung von rekombinantem virus enthalten
DK1117798T3 (da) Fungal transskriptionel aktivator egnet ved fremgangsmåder til produktion af polypeptider
ATE384787T1 (de) Tripeptidyl-aminopeptidase
ATE358725T1 (de) Polypeptide mit aminopeptidaseaktivität und dafür kodierende nukleinsäuren
DE60238449D1 (de) Nukleinsäuren, polypeptide und verfahren zur apoptosemodulation
ATE387220T1 (de) Nukleinsäuren, polypeptide und verfahren zur modulierung von apoptosis
DE69632963D1 (de) Mch3, eine apoptosis-protease, kodierende nukleinsäuren und methoden zur verwendung
ATE335844T1 (de) Verfahren zur bestimmung des kardiovasculären status und zusammensetzungen zu deren verwendung
HK1039793A1 (zh) 一種細胞凋亡蛋白酶天冬氨酸特異性半胱氨酸蛋白酶-14，編碼核酸及其使用方法
ATE408029T1 (de) Verfahren zur herstellung und identifizierung löslicher proteindomänen
DE69934017D1 (de) 2,6-beta-d-fruktanhydrolase enzym und verfahren zu dessen verwendung
DE69931759D1 (de) Methode zur erstellung von genexpressionsprofilen
DE69828874D1 (de) Zusammensetzungen und verfahren zur eliminierung unerwünschter zellen
WO2001096536A3 (en) Aspartic acid proteases and nucleic acids encoding same

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties